- Home
- JFIN vs MYGN Comparison
JFIN vs MYGN Comparison
Compare JFIN & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFIN
- MYGN
- Stock Information
- Founded
- JFIN 2011
- MYGN 1991
- Country
- JFIN China
- MYGN United States
- Employees
- JFIN N/A
- MYGN N/A
- Industry
- JFIN Finance: Consumer Services
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- JFIN Finance
- MYGN Health Care
- Exchange
- JFIN Nasdaq
- MYGN Nasdaq
- Market Cap
- JFIN 547.0M
- MYGN 642.0M
- IPO Year
- JFIN 2019
- MYGN 1995
- Fundamental
- Price
- JFIN $9.84
- MYGN $8.00
- Analyst Decision
- JFIN
- MYGN Hold
- Analyst Count
- JFIN 0
- MYGN 13
- Target Price
- JFIN N/A
- MYGN $13.50
- AVG Volume (30 Days)
- JFIN 69.8K
- MYGN 1.1M
- Earning Date
- JFIN 11-19-2025
- MYGN 11-06-2025
- Dividend Yield
- JFIN 8.02%
- MYGN N/A
- EPS Growth
- JFIN 33.85
- MYGN N/A
- EPS
- JFIN 4.21
- MYGN N/A
- Revenue
- JFIN $908,895,698.00
- MYGN $832,900,000.00
- Revenue This Year
- JFIN N/A
- MYGN $0.17
- Revenue Next Year
- JFIN N/A
- MYGN $5.99
- P/E Ratio
- JFIN $2.32
- MYGN N/A
- Revenue Growth
- JFIN 8.19
- MYGN 3.83
- 52 Week Low
- JFIN $5.18
- MYGN $3.76
- 52 Week High
- JFIN $19.23
- MYGN $23.35
- Technical
- Relative Strength Index (RSI)
- JFIN 33.49
- MYGN 59.00
- Support Level
- JFIN $9.42
- MYGN $7.76
- Resistance Level
- JFIN $10.64
- MYGN $8.59
- Average True Range (ATR)
- JFIN 0.52
- MYGN 0.43
- MACD
- JFIN -0.03
- MYGN -0.03
- Stochastic Oscillator
- JFIN 18.92
- MYGN 52.40
About JFIN Jiayin Group Inc.
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.